AstraZeneca
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.11 | 33 |
| immunology | ×0.73 | 3 |
| rareDisease | ×0.70 | 3 |
| cardiovascular | ×1.50 | 3 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| approved | ×1.43 | 15 |
| phase 1 | ×0.88 | 12 |
| phase 3 | ×1.32 | 7 |
| preclinical | ×0.89 | 5 |
| phase 2 | ×1.12 | 4 |
| discovery | ×0.70 | 4 |
Strategy profile
Based on 15 disclosed transactions, AstraZeneca concentrates its licensing activity in Metabolic, Other, and Oncology. AstraZeneca pays a 1.05x premium over market median, with the strongest premiums in Cardiovascular (1.50x). Their most common deal structure is License, with an average disclosed value of $5.5B. Most recent activity: 2026.
Premium by therapeutic area
How AstraZeneca pays relative to peer medians in each TA
Pipeline coverage & gaps
AstraZeneca has disclosed activity in 4 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 6 | $417M | $4.7B |
| CollaborationPrimary | 6 | $615M | $7.9B |
| Option | 2 | — | $3.2B |
| Acquisition | 1 | $25M | $25M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | TQC3721 | Sino Biopharmaceutical | COPD | unknown | $200M | $2.1B |
| 2026 | siRNA kidney disease program | CSPC Pharma | kidney disease | discovery | $30M | $1.8B |
| 2026 | Next-generation cardiometabolic therapies | CSPC | obesity and type 2 diabetes | unknown | — | $4.7B |
| 2026 | preclinical renal disease molecules | CSPC Pharmaceutical Group | renal diseases | preclinical | — | $1.8B |
| 2026 | Zegfrovy | Dizal Pharmaceutical | locally advanced or metastatic non-small cell lung cancer (NSCLC) | approved | $600M | $1.5B |
| 2026 | Obesity/chronic disease program | CSPC Pharmaceutical | obesity and chronic disease | unknown | $1.2B | $18.5B |
| 2026 | TQC3721 | Sino Bio | COPD | preclinical | $200M | $2.1B |
| 2026 | TQC3721 | Sino Biopharmaceutical | chronic obstructive pulmonary disease (COPD) | phase_2 | $200M | $1.9B |
| 2026 | kidney drug discovery program | CSPC | kidney disease | discovery | — | $1.7B |
| 2026 | Kidney disease collaboration program | CSPC | kidney disease | discovery | $30M | $1.8B |
| 2026 | AI-led chronic disease research | CSPC | chronic diseases | discovery | — | $5.3B |
| 2026 | obesity and weight-related drug candidates | CSPC | obesity | unknown | $1.2B | $18.5B |
| 2026 | EGFR degrader | Pinetree Therapeutics | — | unknown | $25M | $25M |
| 2026 | JAB-23E73 | Jacobio Pharmaceuticals | KRAS-driven cancers | unknown | $100M | $2.0B |
| 2026 | SYH2082 | CSPC Pharmaceutical Group | obesity and type 2 diabetes | preclinical | $1.2B | $18.5B |
How this is computed
For each AstraZeneca deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 47 disclosed deal premiums vs. peer medians. Raw premium 1.047, clamped to [0.7, 1.5].